← Eichor
Condition: Neuroendocrine Tumors Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Neuroendocrine Tumors

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Personalised Immunotherapy Platform
Phase N/A · 3 location(s) · Melanoma Institute Australia · NCT06536257Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine Tumors
Phase 1/Phase 2 · 11 location(s) · National Health Research Institutes, Taiwan · NCT05048901Mirdametinib in Patients With Advanced NF1-mutant Melanoma
Phase 2 · 1 location(s) · Kevin Kim, MD · NCT07237100CapTemY90 for Grade 2/3 NET Liver Metastases
Phase 2 · 4 location(s) · Abramson Cancer Center at Penn Medicine · NCT04339036HX009+ IN10018 With or Without Standard Chemotherapy for Advanced Solid Tumours
Phase 1/Phase 2 · 1 location(s) · Hangzhou Hanx Biopharmaceuticals, Ltd. · NCT06708663Efficacy of First-Line Immunotherapy in Metastatic Melanoma in Slovenia and Identification of Predictive Biomarkers
NA · 1 location(s) · Institute of Oncology Ljubljana · NCT07407166CompArative Analysis Between, Thymic, pulmonaRy and Pancreatic Well Differentiated High Grade Neuroendocrine Tumors
Phase N/A · 1 location(s) · European Institute of Oncology · NCT07429851The Australia and New Zealand Multicentre Upper Gastrointestinal Endoscopic Tissue Resection Study
Phase N/A · 1 location(s) · Western Sydney Local Health District · NCT05804331Urolithin A in Patients With Previously Untreated Solid Tumors Receiving Immune Checkpoint Inhibitors
NA · 1 location(s) · Goethe University · NCT07161310Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination with Pembrolizumab, in Unresecta
Phase 2 · 1 location(s) · Philogen S.p.A. · NCT06284590Neoadjuvant Tebentafusp for Uveal Melanoma
Phase 2 · 2 location(s) · Thomas Jefferson University · NCT06414590Precision Medicine for L/GCMN and Melanoma 1
Phase N/A · 1 location(s) · Fundacion Clinic per a la Recerca Biomédica · NCT0660842061Cu-NODAGA-LM3 PET/CT for the Detection of Neuroendocrine Tumors (COPPER PET in NET)
Phase 1/Phase 2 · 1 location(s) · University Hospital, Basel, Switzerland · NCT06455358Molecular Analysis of Childhood and Adolescent Melanocytic Lesions
Phase N/A · 1 location(s) · St. Jude Children's Research Hospital · NCT02775643Identification of Risk Factors, Exposomics and Genetic Susceptibility of Melanoma in Children, Adolescents and Young Adu
Phase N/A · 6 location(s) · University Hospital Tuebingen · NCT06680323A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
Phase 1/Phase 2 · 15 location(s) · Phanes Therapeutics · NCT05652686The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors
Phase N/A · 1 location(s) · VastBiome · NCT05037825Neoadjuvant Immunotherapy for Patients With High-risk Eye Melanoma
Phase 1 · 1 location(s) · Inge Marie Svane · NCT07501117A Study of ST-1898 for Unresectable or Metastatic Melanoma
Phase 1/Phase 2 · 1 location(s) · Beijing Scitech-Mq Pharmaceuticals Limited · NCT06359860Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
Phase 1 · 1 location(s) · Loyola University · NCT02870244Evaluating Pre-Treatment Vestibular Physical Therapy Rehab for Patients With Vestibular Schwannomas
NA · 1 location(s) · Medical College of Wisconsin · NCT05702749An International Study on Pediatric Patients With Rare Tumors.
Phase N/A · 1 location(s) · Azienda Ospedaliera di Padova · NCT07072143An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancr
Phase 3 · 2 location(s) · Jiangsu HengRui Medicine Co., Ltd. · NCT05884255Safety, Tolerability and Preliminary Efficacy of NEUK203-13 in Refractory Neuroendocrine Tumor Patients
Phase 1 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT07366658BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
Phase 1/Phase 2 · 25 location(s) · BioInvent International AB · NCT04752826SwissNET - a Registry for Neuroendocrine Tumours in Switzerland
Phase N/A · 55 location(s) · Insel Gruppe AG, University Hospital Bern · NCT01039922A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors
Phase 1/Phase 2 · 15 location(s) · Krystal Biotech, Inc. · NCT05970497Protocol ITANET - Registry
Phase N/A · 37 location(s) · Italian Association Neuroendocrine Tumors · NCT04282083BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or S
Phase 2 · 225 location(s) · National Cancer Institute (NCI) · NCT05136196Duration of Anti-PD-1 Therapy in Metastatic Melanoma
Phase 3 · 30 location(s) · Canadian Cancer Trials Group · NCT02821013
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.